Department of Otolaryngology - Head and Neck Surgery, University of Missouri, Columbia, Missouri.
Kansas City University of Medicine and Biosciences, Kansas City, Missouri.
Head Neck. 2019 May;41(5):1304-1311. doi: 10.1002/hed.25562. Epub 2019 Jan 10.
The objective of this study was to determine survival outcomes in patients who underwent retreatment of recurrent cases of cutaneous melanoma of the head and neck (CMHN).
Retrospective review of all patients who were treated for primary clinical stage I or II CMHN between January 1, 2000 and December 31, 2015.
Twenty percent (33/168) of the patients developed a recurrence. Sixty-six percent (4/6) of patients who developed local recurrence first and 50% (3/6) of patients who developed regional recurrence first were alive without evidence (NED) of disease at last follow-up, while 0% (0/21) of patients who developed distant or simultaneous recurrences first were NED at last follow-up. Among the 7 patients who were NED, the mean time from recurrence to last follow-up was 735 days.
Of patients with isolated local or regional recurrences, 58% (7/12) obtained durable curative treatment for recurrent melanoma.
本研究旨在确定头颈部皮肤黑色素瘤（CMHN）复发病例再治疗患者的生存结局。
回顾性分析 2000 年 1 月 1 日至 2015 年 12 月 31 日期间接受原发性临床 I 期或 II 期 CMHN 治疗的所有患者。
20%（33/168）的患者出现复发。66%（4/6）首先出现局部复发的患者和 50%（3/6）首先出现区域复发的患者在最后一次随访时无疾病证据（NED），而首先出现远处或同时复发的患者无一例 NED 在最后一次随访时。在 7 例无疾病证据的患者中，从复发到最后一次随访的平均时间为 735 天。
在孤立的局部或区域复发患者中，58%（7/12）的患者获得了复发性黑色素瘤的持久治愈治疗。
